停用低剂量利伐沙班对慢性冠脉或外周动脉疾病患者的心血管影响
基于COMPASS试验,慢性冠脉或外周动脉疾病患者随机接受利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次或阿司匹林单药,中位随访23个月后因联合治疗获益而提前终止。转为非研究阿司匹林后,原联合治疗组复合终点和心血管死亡与阿司匹林组相似,但卒中发生率更高,包括换药后前6个月缺血性卒中显著增加。
要点
- 随机治疗期联合治疗较阿司匹林降低复合终点、卒中和心血管死亡。
- 提前停药转为非研究阿司匹林后联合治疗的心血管获益丧失。
- 换药后卒中超额,前6个月缺血性卒中显著增加。
核心结论
- 停用研究用利伐沙班和阿司匹林改为非研究阿司匹林,与心血管获益丧失和卒中超额相关。
研究设计与样本
- 基于COMPASS随机试验的事后分析,随机治疗期n=18 278,停药后转为非研究阿司匹林期n=14 068。
主要发现
- 随机治疗期联合治疗较阿司匹林降低复合终点(2.2 vs 2.9/100 py,HR 0.76,95%CI 0.66~0.86)。
- 随机治疗期联合治疗较阿司匹林降低卒中(0.5 vs 0.8/100 py,HR 0.58,95%CI 0.44~0.76)和心血管死亡(0.9 vs 1.2/100 py,HR 0.78,95%CI 0.64~0.96)。
- 提前停药后1.02年,原联合治疗组与阿司匹林组复合终点(2.1 vs 2.0/100 py,HR 1.08,95%CI 0.84~1.39)和心血管死亡(1.0 vs 0.8/100 py,HR 1.26,95%CI 0.85~1.86)相似。
- 提前停药后1.02年,原联合治疗组卒中更高(0.7 vs 0.4/100 py,HR 1.74,95%CI 1.05~2.87),换药后前6个月缺血性卒中显著增加。
关键数值与推荐
- COMPASS试验中位随访23个月后因联合治疗获益而提前终止随机抗栓治疗。
- 试验注册号NCT01776424。
临床怎么用
- 对慢性冠脉或外周动脉疾病患者,停用低剂量利伐沙班联合阿司匹林而转为阿司匹林单药时,需警惕心血管获益丧失和卒中风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients with chronic coronary or peripheral artery disease enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, randomised antithrombotic treatments were stopped after a median follow-up of 23 months because of benefits of the combination of rivaroxaban 2.5 mg two times per day and aspirin 100 mg once daily compared with aspirin 100 mg once daily. We assessed the effect of switching to non-study aspirin at the time of early stopping. METHODS: Incident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068). RESULTS: During randomised treatment, the combination compared with aspirin reduced the composite (2.2 vs 2.9/100 py, HR: 0.76, 95% CI 0.66 to 0.86), stroke (0.5 vs 0.8/100 py, HR: 0.58, 95% CI 0.44 to 0.76) and cardiovascular death (0.9 vs 1.2/100 py, HR: 0.78, 95% CI 0.64 to 0.96). During 1.02 years after early stopping, participants originally randomised to the combination compared with those randomised to aspirin had similar rates of the composite (2.1 vs 2.0/100 py, HR: 1.08, 95% CI 0.84 to 1.39) and cardiovascular death (1.0 vs 0.8/100 py, HR: 1.26, 95% CI 0.85 to 1.86) but higher stroke rate (0.7 vs 0.4/100 py, HR: 1.74, 95% CI 1.05 to 2.87) including a significant increase in ischaemic stroke during the first 6 months after switching to non-study aspirin. CONCLUSION: Discontinuing study rivaroxaban and aspirin to non-study aspirin was associated with the loss of cardiovascular benefits and a stroke excess. TRIAL REGISTRATION NUMBER: NCT01776424.
引用
- Dagenais GR, Dyal L, Bosch JJ, et al. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 2021. PMID: 34021038. doi:10.1136/heartjnl-2020-318758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。